Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

5-HT(3) antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, Jay W, Moon, Thomas E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733872/
https://www.ncbi.nlm.nih.gov/pubmed/23930078
http://dx.doi.org/10.2147/CMAR.S34352
_version_ 1782279421807296512
author Mason, Jay W
Moon, Thomas E
author_facet Mason, Jay W
Moon, Thomas E
author_sort Mason, Jay W
collection PubMed
description 5-HT(3) antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.
format Online
Article
Text
id pubmed-3733872
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37338722013-08-08 Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management Mason, Jay W Moon, Thomas E Cancer Manag Res Review 5-HT(3) antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class. Dove Medical Press 2013-07-29 /pmc/articles/PMC3733872/ /pubmed/23930078 http://dx.doi.org/10.2147/CMAR.S34352 Text en © 2013 Mason and Moon, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Mason, Jay W
Moon, Thomas E
Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title_full Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title_fullStr Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title_full_unstemmed Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title_short Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
title_sort use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733872/
https://www.ncbi.nlm.nih.gov/pubmed/23930078
http://dx.doi.org/10.2147/CMAR.S34352
work_keys_str_mv AT masonjayw useandcardiovascularsafetyoftransdermalandothergranisetronpreparationsincancermanagement
AT moonthomase useandcardiovascularsafetyoftransdermalandothergranisetronpreparationsincancermanagement

Ejemplares similares